About blinatumomab + vial
Bispecific CD19-directed T-cell engager
Used for
- Treats certain types of B-cell acute lymphoblastic leukemia (ALL) in adults and children.
Usual adult dose
Given by continuous intravenous infusion in treatment cycles; dose depends on treatment phase and patient factors.
Usual dose in children
Given by continuous intravenous infusion in treatment cycles; dose is based on body surface area and treatment phase.
Common side effects
- Fever
- Headache
- Low blood-cell counts
- Infusion-related reactions
Important warnings
- Can cause serious neurologic effects, including seizures and confusion.
- Can cause cytokine release syndrome, a potentially life-threatening inflammatory reaction.
- Requires close monitoring, especially when starting treatment or increasing the dose.
- May cause serious infections or liver problems.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for two days after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for two days after the last dose.
Interactions
- Other medicines that affect the immune system may increase risks; review all medicines with the treatment team.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.